BI-1467335 HCl (BI1467335; PXS-4728A; PXS4728A) is a novel and potent SSAO/VAP inhibitor with the potential to be used for the treatment of non-alcoholic steatohepatitis and COPD. SSAO (semicarbazide-sensitive amine oxidase) is related to the migration of neutrophils during acute lung inflammation, pulmonary infection and airway hyperractivity.
Physicochemical Properties
| Molecular Formula | C15H21N2O2F.HCL |
| Molecular Weight | 316.799 |
| Exact Mass | 316.135 |
| CAS # | 1478364-68-9 |
| Related CAS # | 1478364-68-9 (HCl);1478364-40-7; |
| PubChem CID | 71812246 |
| Appearance | White to yellow solid powder |
| LogP | 4.299 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 4 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 21 |
| Complexity | 342 |
| Defined Atom Stereocenter Count | 0 |
| SMILES | CC(C)(C)NC(=O)C1=CC=C(C=C1)OC/C(=C/F)/CN.Cl |
| InChi Key | AEMZEDNMNLIDSL-YGCVIUNWSA-N |
| InChi Code | InChI=1S/C15H21FN2O2.ClH/c1-15(2,3)18-14(19)12-4-6-13(7-5-12)20-10-11(8-16)9-17;/h4-8H,9-10,17H2,1-3H3,(H,18,19);1H/b11-8+; |
| Chemical Name | 4-[(E)-2-(aminomethyl)-3-fluoroprop-2-enoxy]-N-tert-butylbenzamide;hydrochloride |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| References |
[1]. The Inhibitor of Semicarbazide-Sensitive Amine Oxidase, PXS-4728A, Ameliorates Key Features of Chronic Obstructive Pulmonary Disease in a Mouse Model. Br J Pharmacol. 2016 Nov;173(22):3161-3175. |
Solubility Data
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~789.14 mM) H2O : ~100 mg/mL (~315.66 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.08 mg/mL (6.57 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 4: 25 mg/mL (78.91 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with heating and sonication. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1566 mL | 15.7828 mL | 31.5657 mL | |
| 5 mM | 0.6313 mL | 3.1566 mL | 6.3131 mL | |
| 10 mM | 0.3157 mL | 1.5783 mL | 3.1566 mL |